A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature

BackgroundEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. There are many uncommon and rare mutations in the EGFR gene. The efficacy of the EGFR-TKIs is largely unknown f...

Full description

Bibliographic Details
Main Authors: Qi Zhu, Mingyun Jiang, Wenfei Li, Shuangli Sun, Jisheng Li, Justin Stebbing, Xiaodong Liang, Ling Peng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
NSCLC
EGFR
rare mutation
tyrosine kinase inhibitor
immune checkpoint inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.912426/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.912426/full

Similar Items